Stifel raises Lucid Group stock price target to $21 following reverse split

Published 08/09/2025, 13:22
© Reuters.

Investing.com - Stifel raised its price target on Lucid Group Inc. (NASDAQ:LCID) to $21.00 from $2.10 on Monday, while maintaining a Hold rating on the electric vehicle manufacturer’s stock. The company, currently valued at $5.66 billion, has seen its stock decline nearly 40% year-to-date, according to InvestingPro data.

The significant price target adjustment reflects Lucid’s 1-for-10 reverse stock split that became effective on September 2, 2025, rather than any fundamental change in the firm’s outlook on the company.

Stifel analyst Stephen Gengaro explained the technical nature of the price target change in a note to investors, emphasizing that the firm’s Hold rating on Lucid stock remains unchanged.

The reverse stock split reduced Lucid’s outstanding shares by combining every 10 shares into a single share, automatically increasing the per-share price by a factor of 10.

Lucid Group, which competes in the luxury electric vehicle market, implemented the reverse split to boost its share price and maintain compliance with stock exchange listing requirements.

In other recent news, Lucid Group, Inc. completed a significant 1-for-10 reverse stock split, reducing its outstanding shares from approximately 3.07 billion to about 307.3 million. This move also decreased Lucid’s authorized common shares from 15 billion to 1.5 billion. Following this stock split, Cantor Fitzgerald adjusted its price target for Lucid to $20.00, maintaining a Neutral rating. Additionally, Lucid announced the completion of a $300 million investment from Uber Technologies, Inc. as part of their joint development program for autonomous vehicles. These vehicles will be manufactured at Lucid’s Arizona facility and will operate on Uber’s ride-hailing platform.

In another development, Lucid Diagnostics received positive attention as Canaccord Genuity reiterated its Buy rating with a $3.00 price target. This reaffirmation followed a meeting where the usage of Lucid’s EsoGuard test was reevaluated by Medicare Administrative Contractors. These recent developments highlight the ongoing strategic moves and partnerships by Lucid Group and its affiliates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.